CYTK
NASDAQCytokinetics Incorporated
Price$80.15-0.16 (-0.20%)
01:30 PM07:45 PM
News · 26 weeks121-10%
2026-01-182026-07-12
Mix7190d
- Insider40(56%)
- Other14(20%)
- SEC Filings8(11%)
- Earnings4(6%)
- Offering3(4%)
- Analyst2(3%)
Latest news
25 items- PRCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the gr
- INSIDERDirector Wysenski Nancy was granted 75 shares, increasing direct ownership by 0.22% to 33,992 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Wierenga Wendell was granted 75 shares, increasing direct ownership by 0.21% to 35,563 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Kaye Edward M. Md was granted 151 shares, increasing direct ownership by 1% to 10,434 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Henderson John T was granted 272 shares, increasing direct ownership by 0.35% to 78,360 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Harrington Robert Arthur was granted 151 shares, increasing direct ownership by 0.69% to 21,932 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Daly James M was granted 151 shares, increasing direct ownership by 5% to 3,390 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERPresident & CEO Blum Robert I sold $615,150 worth of shares (7,500 units at $82.02) and exercised 7,490 shares at a strike of $10.60, decreasing direct ownership by 0.00% to 377,820 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics IncorporatedSCHEDULE 13G/A - CYTOKINETICS INC (0001061983) (Subject)
- INSIDEREVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $303,170 worth of shares (3,500 units at $86.62) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients
- INSIDERPresident & CEO Blum Robert I sold $636,900 worth of shares (7,500 units at $84.92), decreasing direct ownership by 2% to 377,830 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP, Chief Commercial Officer Callos Andrew exercised 15,000 shares at a strike of $23.26 and sold $1,287,000 worth of shares (15,000 units at $85.80) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP, Chief Financial Officer Lee Sung exercised 1,112 shares at a strike of $48.51 and sold $97,622 worth of shares (1,112 units at $87.79) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP, Chief Financial Officer Lee Sung exercised 38,730 shares at a strike of $47.10 and sold $3,187,479 worth of shares (38,730 units at $82.30) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP, Chief Financial Officer Lee Sung exercised 3,134 shares at a strike of $45.83 and sold $266,390 worth of shares (3,134 units at $85.00) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- ANALYSTCytokinetics upgraded by UBS with a new price targetUBS upgraded Cytokinetics from Neutral to Buy and set a new price target of $115.00
- INSIDEREVP Research & Development Malik Fady Ibraham sold $278,285 worth of shares (3,500 units at $79.51) and exercised 3,500 shares at a strike of $7.80 (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSU
- INSIDERPresident & CEO Blum Robert I sold $528,450 worth of shares (7,500 units at $70.46), decreasing direct ownership by 2% to 385,330 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $237,930 worth of shares (3,500 units at $67.98) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Kaye Edward M. Md sold $223,172 worth of shares (2,933 units at $76.09), decreasing direct ownership by 22% to 10,283 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP, Chief Commercial Officer Callos Andrew sold $1,111,200 worth of shares (15,000 units at $74.08) and exercised 15,000 shares at a strike of $23.26 (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Parshall B Lynne sold $370,400 worth of shares (5,000 units at $74.08), decreasing direct ownership by 24% to 15,784 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in GermanyEuropean Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. Marking the first of several planned European launches, the availabi
CYTK FAQ
7 questionsWhat does Cytokinetics Incorporated do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat...Where does CYTK stock trade?
Cytokinetics Incorporated (CYTK) is listed on NASDAQ.What sector and industry is CYTK in?
Cytokinetics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cytokinetics Incorporated go public?
Cytokinetics Incorporated (CYTK) completed its IPO in 2004.What are analysts saying about CYTK?
Cytokinetics Incorporated has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-06-29.What companies are similar to CYTK?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CYTK side-by-side with any of them on Quantisnow.How can I track CYTK on Quantisnow?
Quantisnow aggregates Cytokinetics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYTK to receive live email and push alerts on every new disclosure.